ripretinib

ripretinib Deciphera Pharmaceuticals Announces U.S. Food And Drug Administration Acceptance Of New Drug Application And Priority Review For Ripretinib In Patients With Advanced Gastrointestinal Stromal Tumors WALTHAM, Mass.–(BUSINESS WIRE)–Feb. 12, 2020– Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced

Women patients still missing in heart research

Women remain underrepresented in heart disease research, even though it’s the leading cause of death among women worldwide, researchers say. Women accounted for less than 40% of all people enrolled in cardiovascular clinical trials from